These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The human pineal gland and melatonin in aging and Alzheimer's disease. Wu YH; Swaab DF J Pineal Res; 2005 Apr; 38(3):145-52. PubMed ID: 15725334 [TBL] [Abstract][Full Text] [Related]
4. Suprachiasmatic nucleus and melatonin: reciprocal interactions and clinical correlations. Benarroch EE Neurology; 2008 Aug; 71(8):594-8. PubMed ID: 18711114 [No Abstract] [Full Text] [Related]
5. Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer's disease. Wu YH; Swaab DF Sleep Med; 2007 Sep; 8(6):623-36. PubMed ID: 17383938 [TBL] [Abstract][Full Text] [Related]
6. Human pineal physiology and functional significance of melatonin. Macchi MM; Bruce JN Front Neuroendocrinol; 2004; 25(3-4):177-95. PubMed ID: 15589268 [TBL] [Abstract][Full Text] [Related]
7. [A chronobiological approach in treatment of sleep disturbances in Alzheimer's dementia patients]. Doljansky JT; Dagan Y Harefuah; 2006 Jun; 145(6):437-40, 470. PubMed ID: 16838900 [TBL] [Abstract][Full Text] [Related]
8. Melatonin and melatonergic drugs on sleep: possible mechanisms of action. Srinivasan V; Pandi-Perumal SR; Trahkt I; Spence DW; Poeggeler B; Hardeland R; Cardinali DP Int J Neurosci; 2009; 119(6):821-46. PubMed ID: 19326288 [TBL] [Abstract][Full Text] [Related]
9. The use of melatonin in Alzheimer's disease. Cardinali DP; Brusco LI; Liberczuk C; Furio AM Neuro Endocrinol Lett; 2002 Apr; 23 Suppl 1():20-3. PubMed ID: 12019347 [TBL] [Abstract][Full Text] [Related]
10. Pineal and cortical melatonin receptors MT1 and MT2 are decreased in Alzheimer's disease. Brunner P; Sözer-Topcular N; Jockers R; Ravid R; Angeloni D; Fraschini F; Eckert A; Müller-Spahn F; Savaskan E Eur J Histochem; 2006; 50(4):311-6. PubMed ID: 17213040 [TBL] [Abstract][Full Text] [Related]
11. Melatonin, sleep disturbance and cancer risk. Blask DE Sleep Med Rev; 2009 Aug; 13(4):257-64. PubMed ID: 19095474 [TBL] [Abstract][Full Text] [Related]
12. Clinical perspectives for the use of melatonin as a chronobiotic and cytoprotective agent. Cardinali DP; Furio AM; Reyes MP Ann N Y Acad Sci; 2005 Dec; 1057():327-36. PubMed ID: 16399904 [TBL] [Abstract][Full Text] [Related]
13. [Melatonin: a popular hormone]. Tarquini B; Perfetto F; Tarquini R Minerva Med; 1998 May; 89(5):139-51. PubMed ID: 9676179 [TBL] [Abstract][Full Text] [Related]
16. Decreased MT1 melatonin receptor expression in the suprachiasmatic nucleus in aging and Alzheimer's disease. Wu YH; Zhou JN; Van Heerikhuize J; Jockers R; Swaab DF Neurobiol Aging; 2007 Aug; 28(8):1239-47. PubMed ID: 16837102 [TBL] [Abstract][Full Text] [Related]
17. Drug Insight: the use of melatonergic agonists for the treatment of insomnia-focus on ramelteon. Pandi-Perumal SR; Srinivasan V; Poeggeler B; Hardeland R; Cardinali DP Nat Clin Pract Neurol; 2007 Apr; 3(4):221-8. PubMed ID: 17410109 [TBL] [Abstract][Full Text] [Related]
18. [Sleep disturbances in Alzheimer's disease and other dementias]. Vecchierini MF Psychol Neuropsychiatr Vieil; 2010 Mar; 8(1):15-23. PubMed ID: 20215095 [TBL] [Abstract][Full Text] [Related]
19. Melatonin receptors. An overview for physicians. Zee PC Postgrad Med; 2004 Dec; 116(6 Suppl Primary):10-3. PubMed ID: 19667693 [TBL] [Abstract][Full Text] [Related]
20. Melatonin, human aging, and age-related diseases. Karasek M Exp Gerontol; 2004; 39(11-12):1723-9. PubMed ID: 15582288 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]